# A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

> **NCT06279234** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)
- Obesity

## Interventions

- **DRUG:** Placebo
- **DRUG:** Rosuvastatin
- **DRUG:** Midazolam
- **DRUG:** Omeprazole
- **DRUG:** PF-06954522

## Key facts

- **NCT ID:** NCT06279234
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-20
- **Primary completion:** 2025-04-11
- **Final completion:** 2025-04-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279234, "A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06279234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*